Traduction de «available in hospitals where » (Néerlandais → Français) :

It must even be available in hospitals where there is no specialised staff (psychiatrists, psychologists) present 24 hours a day and 7 days a week.
Même dans les hôpitaux où le personnel spécialisé (psychiatres, psychologues) n’est pas présent 24/24 et 7 jours/semaine, cette prise en charge doit être réalisée.

In hospitals where extensive MRSA transmission occurs over long periods of time in many care units, screening and treating healthcare worker carriers is less effective compared to the considerable financial burden and workload.
Dans les hôpitaux où se produit une transmission importante de MRSA pendant de longues périodes dans beaucoup d'unités de soin, le dépistage et le traitement des membres du personnel soignant porteurs sont moins efficaces, compte tenu de la charge de travail et des charges financières considérables.

139 It implies that community services should be physicians. For the first time, preliminary counts of the number of offered whenever possible, while hospital servicess should be available practising nurses by sector of activity are now available. when ambulatory care cannot provide a good answer to the patient’s needs.
139 It implies that community services should be which evaluates the number of full-time equivalents (FTE) of active offered whenever possible, while hospital servicess should be available physicians. For the first time, preliminary counts of the number of when ambulatory care cannot provide a good answer to the patient’s practising nurses by sector of activity are now available. needs.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

Extavia (USD 26 million), for patients with relapsing forms of multiple sclerosis (MS), was first launched in the European Union in early 2009 and is now available in more than 15 countries, including the US where it was launched recently after regulatory approval was granted in August 2009.
Extavia (USD 26 millions), pour les malades atteints de formes cycliques de sclérose en plaques (SEP), a été commercialisé d’abord dans l’Union européenne début 2009.

Medicines discovered by the institute will be made available at cost to poor patients in those countries where they are most needed.
Les médicaments mis au point par l’Institut seront fournis à prix coûtant aux malades pauvres des pays où les besoins sont les plus urgents.

1. When epidemiological analysis indicates that a substantial number of MRSA cases are transferred to the hospital on a regular basis from other institutions where MRSA are (suspected to be) endemic, it might be safe to screen incoming patients systematically in order to detect MRSA colonisation as soon as possible and nurse the patients accordingly.
1. Quand l'analyse épidémiologique indique qu'un nombre substantiel de cas de MRSA sont transférés à l'hôpital de façon régulière à partir d'autres établissements où les MRSA sont (supposés être) endémiques, il pourrait être prudent de dépister systématiquement les patients entrants afin de détecter la colonisation par MRSA le plus tôt possible et de soigner les patients en conséquence.

A written document must be available for all hospital staff stating clearly which additional precautions must be taken when patients colonised or infected by MRSA are approached.
Un document écrit doit être disponible pour tout le personnel hospitalier énonçant clairement quelles sont les précautions supplémentaires qui doivent être prises quand on aborde des patients colonisés ou infectés par MRSA.

5.2.2 Detection of MRSA carriers among patients The need (number of sites tested, techniques) for screening hospital patients for MRSA largely depends on the objectives and available resources.
5.2.2 Dépistage des porteurs de MRSA parmi les patients La nécessité (nombre de sites testés, techniques) qu’il y a de dépister le MRSA chez les patients hospitalisés dépend en grande partie des objectifs et des ressources disponibles.